The most common site of disease in metastatic castration-resistant prostate cancer (mCRPC) is the bone. The ALSYMPCA study demonstrated that radium-223 significantly improved overall survival (OS) in mCRPC patients with symptomatic bone metastases and without visceral metastases.
Despite notable screening, diagnostic, and therapeutic advances, disparities in prostate cancer incidence and outcomes remain prevalent. Although commonly discussed in the context of men of African descent, disparities also exist based on socioeconomic level, education level, and geographic location.
Androgen receptor (AR) is critical to the initiation, growth, and progression of prostate cancer. Once activated, the AR binds to cis-regulatory enhancer elements on DNA that drive gene expression. Yet, there are 10-100× more binding sites than differentially expressed genes.
To assess the effect of race/ethnicity in cancer-specific mortality (CSM) adjusted for other-cause mortality (OCM) in metastatic prostate cancer patients (mPCa) treated with external beam radiotherapy (EBRT) to the prostate.
Bladder and kidney cancers require invasive procedures for definitive diagnosis, and bladder cancer requires repeated procedures to monitor for disease recurrence. Given the recent work to identify molecular alterations in liquid biopsies to diagnose and monitor these diseases, a synthesis of the growing body of evidence is merited.
White light cystoscopy is the current standard for primary diagnosis and surveillance of bladder cancer. However, cancer changes can be subtle and may be easily missed. With the advancement of deep learning (DL), image recognition by artificial intelligence (AI) proves a high accuracy for image-based diagnosis.
Abstract Background: Prostate cancer in black men is associated with poorer outcomes than their white counterparts. However, most studies reporting this disparity were conducted in localized prostate cancer and primarily in the United States. Methods: Data regarding prostate cancer incidence and mortality for East London between 2008 and 2010 were obtained from the UK National […]
Racial diversity in clinical trials serves as a metric of equality and access to healthcare. However, unfortunately, trial populations frequently do not represent populations they intend to emulate. Current International Committee of Medical Editors (ICJME) guidelines recommend as a minimum, descriptive data on race and ethnicity. Furthermore, US Food and Drug Administration (FDA) guidelines introduced […]
Foundation Medicine and its collaborators recently announced results from a prostate cancer study evaluating the landscape of genomic alterations identified by liquid biopsy in over 3,000 patients and assessing concordance of liquid and tissue biopsy in over 800 patients. The study demonstrated high concordance between targetable alterations identified using circulating tumor DNA (ctDNA) and tissue-based […]
To assess the effect of clinical and pathological variables on cancer-specific and overall survival (OS) in de novo metastatic patients from a collaborative of primarily Latin American countries. Of 4,060 patients with renal cell carcinoma diagnosed between 1990 and 2015, a total of 530 (14.
